ArticlePatient preference and adherence2025

Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study.

Anna Almroth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.